Author/Editor		Stantič-Pavlinič, Mirjana; Levičnik-Stezinar, Snežna; Zaletel-Kragelj, Lijana; Hostnik, Peter
Title		Longevity of lasting specific immunity after primary vaccination against rabies - comparison of ELISA and FAVN tests
Translated title		Trajanje specifične imunosti po primarnem cepljenju proti steklini - primerjava testov ELISA in FAVN
Type		članek
Source		Slov Vet Res
Vol. and No.		Letnik 43, št. 3
Publication year		2006
Volume		str. 119-25
Language		eng
Abstract		The purpose of the study was to monitor the efficacy of primary vaccination against rabies and the need for booster doses. These studies validate at the same time the recent technological improvements in laboratory diagnostics of the level of rabies protection in human sera. Study was done at the level of antibodies considering that an antibody titer 0.5 IU/ml is protective. We used Platelia rabies ELISA kit (BIO-RAD Laboratories) for the detection of rabies anti-glycoprotein antibodies in 41 human sera of previously healthy veterinarian students. Neutralising rabies antibodies were measured simultaneously by fluorescent antibody virus neutralization (FAVN) test as well. Subjects entering the study have received 2 to 8 years prior rabies treatment with human diploid cell vaccine (HDCV, Rabivac, Chiron Germany) according to schedule: one vaccine on 1, 7, 21 and 365 day. Mean level of rabies antibody detected by ELISA was 19.6 EU/ml (SD 18.8 minimum 1 maximum 56). Results were higher in the groups vaccinated recently. Nobody had titer <0 0.5 IU/ml either in ELISA or in FAVN test. In the FAVN test, the average titers were higher and reached 54.4 IU/ml (SD 44.3 minimum 0.7 maximum 152.5). An immune-complex-like reaction occurring after administration of the booster doses of rabies vaccine is one of the reasons to reconsideration of the needs for administration of booster rabies vaccines. At the same time, the need for mass protection of subjects exposed to rabies virus professionally is existing worldwide . The results of these studies indicate that HDCV is highly immunogenic in both FAVN test and ELISA tests. High level of protection is lasting in human sera for at least 8 years. Average levels of detected rabies antibodies were lower in ELISA in comparison with FAVN test. Correlation between two tests was found.
Summary		Namen študije je bil opraviti kontrolo uspešnosti primarnega cepljenja proti steklini in dobiti odgovor na vprašanje ali je morebiti potrebno še dodatno cepljenje. Istočasno smo želeli preveriti laboratorijske izboljšave pri metodah določanja stopnje zaščitnih protiteles proti virusu stekline v serumih fjudi. Študija je izhajali iz podatka, da titer protiteles enak ali višji od 0,5 IU/ml, ščiti človeka pred steklino.V serumu 41 študentov veterine smo v testu ELISA, komplet Platelia (BIO-RAD Laboratories), določali protitelesa proti glikoproteinu virusa stekline. Hkrati smo nivo protiteles določali tudi v seronevtralizacijskem testu z imunofluorescenco (test FAVN). Študenti so bili cepljeni 2 do 8 let pred odvzemom krvnega vzorca s cepivom prod steklini (HDCV, Rabivac, Chiron Germany) po shemi: ena doza 1., 7., 21. in 365. dan. Povprečni titer protiteles, ugotovljen v testu ELISA, je znašal 19,6 EU/ml (SD 18,8 minimum 1 maximum 56). Višje titre smo ugotovili pri skupini, ki je bila cepljena pred kratkim. Nihče ni imel titra protiteles nižjega od 0,5 IU/ml. V testu FaVN smo dobili nekoliko višji titer protiteles, saj je znašal 54,4 IU/ml (SD 44,3, minimum 0,7, maksimum152,5). Nivo protiteles proti virusu stekline v serumu pacienta je uporaben kazalnik potrebe po izvedbi revakcinacije. Hkrati ugotavjamo, da je upravičena široka zaščita proti steklini tistih oseb, ki so poklicno izpostavljene večji možnosti okužbe z virusom stekline. Rezultati te študije kažejo, tako v testu ELISA kot v testu FAVN, da daje cepivo HDCV zadovoljivo zaščito. Ugotovili smo visok titer protiteles še 8 let po izvedbi osnovnega cepljenja. V testu ELISA smo v povprečju ugotovili nižji titer protiteles kot v testu FAVN.
Descriptors		RABIES RABIES VACCINE ANTIBODIES, VIRAL ENZYME-LINKED IMMUNOSORBENT ASSAY FLUORESCENT ANTIBODY TECHNIQUE